Erik X Rivera, MD | |
13975 Connecticut Ave, 2nd Floor, Holy Cross Health Center - Aspen Hill, Aspen Hill, MD 20906-2921 | |
(301) 557-1950 | |
(301) 557-1949 |
Full Name | Erik X Rivera |
---|---|
Gender | Male |
Speciality | Internal Medicine |
Location | 13975 Connecticut Ave, Aspen Hill, Maryland |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1891924866 | NPI | - | NPPES |
D81294 | Other | MD | MARYLAND BOARD OF PHYSICIANS |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207R00000X | Internal Medicine | D81294 (Maryland) | Primary |
Mailing Address | Practice Location Address |
---|---|
Erik X Rivera, MD 13415 Connecticut Ave Ste 100, Aspen Hill, MD 20906-2910 Ph: (301) 557-1950 | Erik X Rivera, MD 13975 Connecticut Ave, 2nd Floor, Holy Cross Health Center - Aspen Hill, Aspen Hill, MD 20906-2921 Ph: (301) 557-1950 |
News Archive
The U.S. Food and Drug Administration today approved Iclusig (ponatinib) to treat adults with chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), two rare blood and bone marrow diseases.
UC Davis biomedical engineer Prof. Alexander Revzin has developed a "lab on a chip" device for HIV testing. Revzin's microfluidic device uses antibodies to "capture" white blood cells called T cells that are affected by HIV. In addition to physically binding these cells the test detects the types and levels of inflammatory proteins (cytokines) released by the cells.
DaVinci Biosciences LLC, of Costa Mesa, CA, announced today the presentation of their safety and feasibility study demonstrating the administration of autologous bone marrow derived stem cells for the treatment of acute and chronic spinal cord injury at Neuroscience 2009, Society for Neuroscience's 39th Annual Meeting, to be held at McCormick Convention Center in Chicago, IL.
Most states do not cover bariatric surgery under the Affordable Care Act (ACA) despite the need for effective treatments for obesity and the minimal impact it has on monthly premiums, according to new research presented here at ObesityWeek 2015, the largest international event focused on the basic science, clinical application and prevention and treatment of obesity.
› Verified 3 days ago